Resonance set for US pilot study
14 September, 2005 by Helen SchullerResonance Health Group (ASX:RHT) has signed a memorandum of understanding with a US radiology service provider for a pilot study in preparation for the commercial launch of its FerriScan diagnostic test.
'Simpler' new NHMRC structure welcomed
12 September, 2005 by Graeme O'NeillAustralia's medical research community has welcomed news of major changes to the nation's sole research funding agency, the National Health and Medical Research Council (NHMRC).
Benitec speculation leads to speeding ticket
12 September, 2005 by Ruth BeranLicence discussions between RNAi specialist Benitec (ASX:BLT) and an undisclosed party caused Bentiec's share price to rise from $0.135 on September 8 to $0.17 on September 9, the company has told the ASX.
CollTech raises $2.27m in placement
12 September, 2005 by Ruth BeranWestern Australian collagen purification company CollTech (ASX:CAU) has raised $2.27 million after fees from its recent private placement and share purchase plan.
Bring back our best and brightest
12 September, 2005 by Ruth BeranThey were set up to bring key Australian scientists back from overseas. But nearly two thirds of last year's crop of Australian Research Council (ARC) Federation Fellowships was awarded to scientists already living here.
UQ researchers race to develop MRI contrast agent
08 September, 2005 by Ruth BeranScientists around the world are racing to create the first 'smart' contrast agent to enhance the use of MRI in measuring biological processes in the body, and three early-career researchers at the University of Queensland (UQ) are in the running.
Acrux reports on testosterone product trials
08 September, 2005 by Ruth BeranSpecialty pharmaceutical company Acrux (ASX:ACR) has reported positive results from two more clinical studies of its Testosterone MD-Lotion treatment for testosterone deficiency in men.
Ventracor recalls external components of VentrAssist
08 September, 2005 by Helen SchullerArtificial heart company Ventracor (ASX:VCR) has recalled the external components of its VentrAssist left ventricular assist system (LVAS) following the discovery of an anomaly in certain lots of the cable which connects the externally worn controller to the implanted VentrAssist blood pump.
Uniseed receives further $16m from founding investors
08 September, 2005 by Ruth BeranThe Universities of Queensland and Melbourne, the founding investors in university based pre-seed venture fund Uniseed, have extended their commitments to the fund by a further $8 million each.
New patents for Neuren
07 September, 2005 by Helen SchullerNeuren Pharmaceuticals (ASX:NEU) has been issued two additional US patents expanding its portfolio to Parkinson's disease and hypertension.
A sweet $22 million for Queensland research centre
07 September, 2005 by Helen SchullerGriffith University plans to almost triple its number of scientists from 55 to 155 over the next seven years to create the largest glycomics institute in the world following a commitment by the Queensland government and the university to spend AUD$22 million.
CSIRO develops sound technology for rapid screening
06 September, 2005 by Helen SchullerPoint-of-care blood screening at airports, schools and the local GP's office could be a reality following the development of a micro-technology at the CSIRO that uses sound to mix blood.
Eiffel hanging on as cash dwindles
05 September, 2005 by Helen SchullerSydney drug re-engineering company Eiffel Technologies (ASX:EIF) has released its results for the 2004-05 financial year, showing losses of AUD$3.5 million -- down 8.3 per cent from the previous year -- but less than $630,000 cash in the bank.
GTG lists on Nasdaq national market
05 September, 2005 by Ruth BeranMelbourne-based Genetic Technologies (ASX:GTG) has listed its Level II American Depositary Receipts (ADRs) on the US Nasdaq national market.
In brief: Avantogen, Novogen, Peplin, ResMed
02 September, 2005 by Staff WritersAlastair Hood has resigned as a director of Avantogen (ASX:ACU), formerly Australian Cancer Technology, citing increased corporate and travel commitments with his investment company Bluespire as the reason for his departure.
